Penzberg, Germany, 31 March 2011
Roche Diagnostics Announces the Appointment of Robert Yates as New Head of Roche Applied Science
Roche Diagnostics (SIX: RO, ROG; OTCQX: RHHBY), announced today that effective from April 1, Robert Yates has been appointed as new Head of Roche Applied Science. He succeeds Manfred Baier, who will be retiring from Roche at the end of 2011. Robert Yates subsequently held increasing leadership positions in R&D, engineering and process management within Roche Diagnostics, in Indianapolis and in Roche´s headquarters in Basel. Most recently he served as Global Head of Business Development and Licensing of Roche Diagnostics. Robert Yates will report to Daniel ODay, COO of Roche Diagnostics.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare, with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.